MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

Soligenix Inc

Healthcare US SNGX


Last update at 2024-07-11T14:48:00Z

Day Range


52 Week Range



  • Previous Close 7.73
  • Market Cap5.71M
  • Volume1026642
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-7.69139M
  • Revenue TTM0.84M
  • Revenue Per Share TTM0.11
  • Gross Profit TTM 0.10M
  • Diluted EPS TTM-0.6


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -14.95327M -13.41572M -18.52541M -9.96627M -8.89997M
Minority interest - - - - -
Net income -13.79834M -12.55097M -17.68852M -9.35559M -8.89997M
Selling general administrative 6.69M 4.85M 3.98M 3.48M 2.95M
Selling and marketing expenses - - - - -
Gross profit 0.40M 0.10M 0.54M 1.06M 0.64M
Reconciled depreciation 0.02M 0.03M 0.06M 0.05M 0.04M
Ebit -14.10604M -12.96612M -18.49115M -10.10743M -9.05898M
Ebitda -14.07555M -12.90120M -18.42878M -10.04517M -9.01492M
Depreciation and amortization 0.03M 0.06M 0.06M 0.06M 0.04M
Non operating income net other - - - 0.15M 0.16M
Operating income -14.10604M -12.96612M -18.49115M -10.10743M -9.05898M
Other operating expenses 15.05M 13.79M 20.85M 14.74M 14.30M
Interest expense 0.82M 0.86M 0.01M 0.13M 0.00000M
Tax provision -1.15494M -0.86474M -0.83689M -0.61068M 0.00000M
Interest income - - - 0.15M 0.16M
Net interest income -0.82261M -0.86258M -0.01088M 0.15M 0.16M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -1.15494M -0.86474M -0.83689M -0.61068M 0.16M
Total revenue 0.95M 0.82M 2.36M 4.63M 5.24M
Total operating expenses 14.50M 13.06M 19.03M 11.17M 9.70M
Cost of revenue 0.55M 0.73M 1.82M 3.57M 4.60M
Total other income expense net -0.84724M -0.44960M -0.03427M 0.14M 0.16M
Discontinued operations - - - - -
Net income from continuing ops -13.79834M -12.55097M -17.68852M -9.35559M -8.89997M
Net income applicable to common shares - -12.55097M -17.68852M -9.35559M -8.89997M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 9.80M 14.28M 26.87M 19.89M 7.78M
Intangible assets - - - - 0.02M
Earning assets - - - - -
Other current assets 0.87M 0.27M 0.28M 0.23M 0.61M
Total liab 7.27M 16.75M 16.15M 16.15M 6.32M
Total stockholder equity 2.52M -2.47083M 10.72M 3.74M 1.46M
Deferred long term liab - - 0.02M 0.05M 0.04M
Other current liab 2.67M 2.64M 3.26M 3.51M 3.46M
Common stock 0.01M 0.00291M 0.04M 0.03M 0.02M
Capital stock 0.01M 0.00291M 0.04M 0.03M 0.02M
Retained earnings -225.70418M -219.56345M -205.76511M -193.21413M -175.52561M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.17M 0.15M 0.06M
Cash 8.45M 13.36M 26.04M 18.68M 5.42M
Cash and equivalents - - - - -
Total current liabilities 6.15M 16.52M 6.29M 6.08M 6.31M
Current deferred revenue - - - - -
Net debt -4.95160M -3.11935M -16.08159M -8.17050M -5.29348M
Short term debt 2.37M 10.01M 0.11M 0.44M 0.12M
Short long term debt 2.25M 9.90M - 0.32M -
Short long term debt total 3.49M 10.24M 9.96M 10.51M 0.13M
Other stockholder equity 228.19M 217.06M 216.40M 196.95M 177.01M
Property plant equipment - - 0.13M 0.25M 0.16M
Total current assets 9.51M 13.85M 26.57M 19.47M 7.49M
Long term investments - - - - -
Net tangible assets - - 10.72M 3.72M 1.40M
Short term investments - - - - -
Net receivables 0.20M 0.22M 0.24M 0.56M 1.46M
Long term debt 1.01M - 9.86M 9.95M 0.00615M
Inventory 0.00000M - - - -
Accounts payable 1.11M 3.87M 2.93M 2.13M 2.74M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.02M 0.02M 0.04M -0.02434M -0.04501M
Additional paid in capital - - - - -
Common stock total equity - - - 0.03M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -193.21413M -175.52561M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.02M 0.07M 0.17M 0.17M 0.10M
Deferred long term asset charges - - - - -
Non current assets total 0.29M 0.43M 0.30M 0.42M 0.28M
Capital lease obligations 0.23M 0.34M 0.11M 0.23M 0.13M
Long term debt total - - - 10.07M 0.00615M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.01307M -0.01179M -0.00715M -0.02471M -0.00093M
Change to liabilities - 1.13M -1.15716M 1.97M 1.02M
Total cashflows from investing activities - -0.01179M -0.00715M -0.02471M -0.00093M
Net borrowings - -0.00615M 10.41M -0.13208M -0.00680M
Total cash from financing activities 0.08M 19.06M 24.68M 4.01M 8.42M
Change to operating activities - -0.54064M 0.85M -1.01471M 0.07M
Net income -13.79834M -12.55097M -17.68852M -9.35559M -8.89997M
Change in cash -12.68428M 7.37M 13.26M -3.56301M 1.17M
Begin period cash flow 26.04M 18.68M 5.42M 8.98M 7.81M
End period cash flow 13.36M 26.04M 18.68M 5.42M 8.98M
Total cash from operating activities -12.64902M -11.73962M -11.45443M -7.50957M -7.24463M
Issuance of capital stock 0.08M 19.71M 14.62M 4.14M 8.68M
Depreciation 0.02M 0.03M 0.06M 0.05M 0.04M
Other cashflows from investing activities - - - 0.00550M 0.00100M
Dividends paid -0.00004M - - - -
Change to inventory - - - - -
Change to account receivables 0.02M 0.06M 0.82M 0.18M -0.27546M
Sale purchase of stock - - 0.00499M 4.14M 8.68M
Other cashflows from financing activities -0.00249M -0.64150M 10.07M -0.13020M -0.25189M
Change to netincome - 0.08M 5.47M 1.85M 1.66M
Capital expenditures 0.01M 0.01M 0.00715M 0.03M 0.00193M
Change receivables - - 0.84M - -
Cash flows other operating - - 5.38M - -
Exchange rate changes - - 0.04M -0.03419M -0.00367M
Cash and cash equivalents changes - - 13.26M -3.56301M 1.17M
Change in working capital 0.43M 0.65M 0.51M 1.14M 1.23M
Stock based compensation 0.33M 0.36M 0.41M 0.38M 0.38M
Other non cash items 0.37M 0.19M 5.25M 0.28M 0.00148M
Free cash flow -12.66209M -11.75141M -11.46157M -7.53978M -7.24656M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Soligenix Inc
-1.2799 16.56% 6.45 - - 4.84 1.61 1.87 0.11
Novo Nordisk A/S
-1.54 1.08% 141.20 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
-0.09 0.06% 141.25 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
-1.14 0.23% 490.48 29.67 24.33 10.38 5.83 9.33 20.00
Regeneron Pharmaceuticals Inc
10.39 0.97% 1081.52 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News


Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia, Ib, and Ic clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Soligenix Inc

29 Emmons Drive, Princeton, NJ, United States, 08540

Key Executives

Name Title Year Born
Dr. Christopher J. Schaber Ph.D. Chairman of Directors, CEO & Pres 1966
Mr. Jonathan L. Guarino CPA, CGMA Sr. VP, CFO & Corp. Sec. 1973
Dr. Oreola Donini Ph.D. Sr. VP & Chief Scientific Officer 1972
Dr. Richard C. Straube M.D., MSc. Sr. VP & Chief Medical Officer 1952
Mr. Richard L. Dunning Exec. Officer 1946
Dr. Christopher J. Schaber Ph.D. Chairman of the Board of Directors, CEO & President 1966
Mr. Jonathan L. Guarino CPA, CGMA Senior VP, CFO & Corporate Secretary 1973
Dr. Oreola Donini Ph.D. Senior VP & Chief Scientific Officer 1972
Dr. Richard C. Straube M.D., MSc. Senior VP & Chief Medical Officer 1952

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.